At recent prices, $100 is enough to buy shares of both Royalty Pharma and AT&T. AT&T offers a high dividend yield, and it ...

Royalty Pharma plc (NASDAQ:RPRX), a company specializing in pharmaceutical preparations, announced a significant milestone following the U.S. Food and Drug Administration's (FDA) approval of a new ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.

US antivirals giant Gilead Sciences today announced that it has signed non-exclusive, royalty-free voluntary licensing ...

UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

Royalty Pharma plc (NASDAQ:RPRX), a company specializing in pharmaceutical preparations, announced a significant milestone following the U.S. Food and Drug Administration's (FDA) approval of a new ...

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Royalty Pharma plc is a key player in the biopharmaceutical industry, specializing in the acquisition of biopharmaceutical royalties and funding innovation. With a focus on collaboration ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Wednesday said it has signed royalty-free licensing agreements with six pharmaceutical manufacturers to manufacture and supply generic versions of the ...

If approved, the six manufacturers – Dr Reddy’s Laboratories Limited, Emcure, Eva Pharma, Ferozsons Laboratories Limited, ...